Interferon free hepatitis C treatment regimens: The beginning of another era

被引：7
作者：
Fred Poordad
Grace M. Chee
机构：
[1] Hepatology and Liver Transplantation, Cedars-Sinai Medical Center, Los Angeles, CA 90048
[2] Hepatology Department, Cedars-Sinai Medical Center, Los Angeles, CA 90048
来源：
Current Gastroenterology Reports | 2012年 / 14卷 / 1期
关键词：
Direct acting antivirals; Hepatitis C; Interferon; Interferon free; Polymerase inhibitor; Protease inhibitor; Ribavirin; SVR;
D O I：
10.1007/s11894-011-0229-1
中图分类号：
学科分类号：
摘要：
Hepatitis C is a virus affecting millions worldwide and is a major health risk. With the potentially severe adverse event profile of the current backbone of therapy, interferon, there is an impetus to discover interferon free treatment regimens. With the development of new oral direct acting antivirals, interferon free regimens may be available in the next few years. This article discusses some of the preliminary data from interferon free studies. © 2011 Springer Science+Business Media, LLC.
引用
收藏
页码：74 / 77
页数：3
相关论文
共 25 条
[11]  
Flamm S., Lawitz E., Jacobson I., Et al., High Sustained Virologic Response (SVR) among genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when re-treated with boceprevir (BOC) plus peginterferon alfa-2A/ribavirin, J Hepatol, 54, (2011)
[12]  
Bacon B.R., Gordon S.C., Lawitz E., Et al., Boceprevir for previously treated chronic HCV genotype 1 infection, N Engl J Med., 364, pp. 1207-1217, (2011)
[13]  
Poordad F., Chee G.M., Pharmacology and mechanisms of action of antiviral drugs: Ribavirin analogues, Advanced Therapy for Hepatitis C Infection, (2011)
[14]  
Fried M.W., Shiffman M.L., Reddy K.R., Et al., Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection, N Engl J Med, 347, pp. 975-982, (2002)
[15]  
Poordad F., McCone Jr. J., Bacon B.R., Et al., Boceprevir for untreated chronic HCV genotype 1 infection, N Engl J Med., 364, pp. 1195-1206, (2011)
[16]  
Jacobson I.M., McHutchison J.G., Dusheiko G., Et al., Telaprevir for previously untreated chronic hepatitis C virus infection, N Engl J Med., 364, pp. 2405-2416, (2011)
[17]  
Gale Jr. M., Katze M.G., Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase, Pharmacology and Therapeutics, 78, 1, pp. 29-46, (1998)
[18]  
Ge D., Fellay J., Thompson A.J., Et al., Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance, Nature., 461, pp. 399-401, (2009)
[19]  
Thompson A.J., Muir A.J., Sulkowski M.S., Et al., IL28B Polymorphism Improves Viral Kinetics and Is the Strongest Pre-treatment Predictor of SVR in HCV-1 Patients, Gastroenterology, 139, pp. 120-129, (2010)
[20]  
Poordad F., Bronowicki J.-P., Gordon S.C., Et al., IL28B Polymorphism Predicts Virologic Response in Patients with Hepatitis C Genotype 1 Treated with Boceprevir (Boc) Combination Therapy, Gastroenterology, (2011)
123